The early GO decision and Orphan Drug Designation materially de-risk claseprubart's clinical and regulatory path. Monitor for CAPTIVATE Part B top-line guidance by YE 2026 and Phase 3 gMG trial initiation in mid-2026 as the next major catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $90.42entry
- T+1 · 6mo ago −5.47%α −5.14% · $85.47
- T+5 · 6mo ago −4.72%α −5.85% · $86.15
- T+20 · 6mo ago −6.03%α −8.81% · $84.97
- T+60 · 4mo ago +18.25%α +16.19% · $106.92
Price Chart
How similar events traded
Executive Summary
Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/share) and highlighted major pipeline progress: early GO decision in Phase 3 CAPTIVATE CIDP trial, FDA Orphan Drug Designation for claseprubart in myasthenia gravis, and selection of three initial indications for DNTH212. Cash of $1.2B provides runway into 2030, removing near-term financing risk.
Key Financial Metrics
Key Facts
- Early GO decision reached in Phase 3 CAPTIVATE CIDP trial after 20 confirmed responders with <40 patients completing Part A.
- Claseprubart granted FDA Orphan Drug Designation for myasthenia gravis.
- Cash, cash equivalents and investments of $1.2B as of March 31, 2026, providing runway into 2030.
- Closed upsized public offering with gross proceeds of ~$719 million on March 12, 2026.
- Net loss for Q1 2026: $40.8M ($0.85/share) vs. $29.5M ($0.82/share) in Q1 2025.
- Phase 2 MoMeNtum MMN trial top-line results on track for Q4 2026; Phase 3 EMERGE gMG trial to initiate mid-2026 with 2H 2028 top-line.
- First three priority indications for DNTH212: Sjögren's Disease, SLE, Dermatomyositis.
Financial Impact
Q1 2026 net loss of $40.8M ($0.85/share) vs $29.5M ($0.82/share) in prior year; revenue of $463K (license) vs $1.163M. No financial guidance provided.
Risk Factors
- Clinical trial failure in upcoming Phase 3 or Phase 2 readouts.
- Competition from approved complement inhibitors and other therapies.
- Dilution from the March 2026 offering; ~48M shares outstanding post-offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001690585-26-000021 |
| Document: dnth-20260505.htm | 0001690585-26-000021 |
| Document: 0001690585-26-000021-index-headers.html | 0001690585-26-000021 |
| Document: 0001690585-26-000021-index.html | 0001690585-26-000021 |
| Document: 0001690585-26-000021.txt | 0001690585-26-000021 |
| 8-K Data (Synthetic) | 0001690585-26-000021 |
Track record
23 reports on DNTH
7 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers